Key points from article :
Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353.
EA-2353 is a photoreceptor regeneration treatment for retinitis pigmentosa (RP).
RP is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.
EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells.
Principal investigator, Mark Pennesi, said: “This ... new treatment has the potential to be a major game-changer for patients with RP who currently have no other options.”
Endogena’s artificial intelligence-driven drug discovery platform, combined with molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells, provides a potential new treatment to tackle degenerative conditions related to aging and genetic disorders.
